MINNEAPOLIS–(BUSINESS WIRE)–Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies and lung protective therapies for COVID-19, announced the arrival of the renowned venture capitalist and life sciences industry expert Jake R. Nunn to the Company’s Board of Directors.
“We cannot stress enough the importance of bringing Mr. Nunn onto our board of directors,” said Ronald J. Zenk, CEO of Humanetics. “He brings exceptional knowledge and experience from venture capitalists and institutional investors, with a focus on growing businesses and maximizing shareholder value. We are incredibly lucky to collaborate with him.
Dr. Nunn’s insights will be invaluable as Humanetics’ proprietary drug BIO 300 gains traction for its potential to mitigate the harmful effects of radiation exposure on combatants, first responders and healthy tissue in certain patients with cancer, as well as improving outcomes for COVID-19 long carriers.
“I am delighted to join the Humanetics Board of Directors,” said Mr. Nunn. “After more than 25 years of experience in the life sciences industry, I pivoted to work as an independent advisor precisely to have the opportunity to engage and support clinical-stage specialty pharma companies. like Humanetics to help them position and prepare for their next phase of growth.”
BIO 300 is currently under development for multiple applications. BIO 300 is currently in a Phase 2b trial evaluating the drug’s clinical utility in protecting lung tissue against the long-term effects of COVID-19, and recently completed a Phase 1b/2a clinical trial in patients with lung cancer. BIO 300 has also received significant attention, funding and research for its potential to mitigate the effects of radiation among combatants and civilians in the event of a nuclear attack or radiological incident.
“Among Mr. Nunn’s myriad skillset is a remarkable ability to guide clinical-stage companies like Humanetics through the steps necessary to maximize their value and strategic options,” added Mr. Zenk. “The timing is perfect, as we are steadily advancing through the clinical trial phases and approaching the point of proof of efficacy. Mr. Nunn is very familiar with the process and the people involved, and we are grateful to have his expertise on our side.
Mr. Nunn has 25 years of experience in the life sciences industry as an investor, independent director, research analyst and investment banker. He is currently an independent advisor to life science companies and a venture capital advisor at New Enterprise Associates, or NEA, where he was a partner from 2006 to 2018. He has held executive positions in several companies that have is the subject of successful acquisitions and has particular expertise in late-stage specialty pharmaceuticals. He holds an MBA from the Stanford Graduate School of Business and a degree in economics from Dartmouth College. Mr. Nunn holds the Chartered Financial Analyst designation, is a member of the CFA Society of San Francisco and recently completed the Stanford GSB Directors’ Consortium Executive Education Program.
About Humanetics Corporation
Humanetics is a clinical-stage specialty pharmaceutical company committed to the accelerated discovery, development and commercialization of proprietary medicines in markets with urgent and unmet needs, with a focus on medical countermeasures to prevent harm by exposure to radiation, for the purpose of protection against cancer. radiation therapy and to guard against the long-term adverse effects of COVID-19. For more information, visit www.humaneticscorp.com.
